Every material Form 8-K Cosmos Health Inc. has filed with the SEC since August 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cosmos Health said in an October 19 release and an October 20 CEO letter that it expects fourth-quarter 2026 U.S. revenue of about $15 million and gross profit of about $10.5 million, and it reaffirmed full-year 2026 revenue above $90 million. Preliminary nine-month revenue was about $54.3 million, up 19%, but the fourth-quarter and full-year figures are company expectations, and the nine-month figures are preliminary and unaudited.
Preliminary nine-month 2026 revenue of about $54.3 million, up 19% year over year
Expected fourth-quarter 2026 U.S. revenue of about $15 million, with gross profit of about $10.5 million at a roughly 70% gross margin
Full-year 2026 revenue expected to surpass $90 million, implying fourth-quarter revenue of about $35.7 million or more, up about 81%
Active U.S. subscriptions reached 8,940 as of October 19, 2026, up 42% from 6,287 on October 14; more than 5.1 million shares repurchased for about $1.1 million
Cosmos Health reported preliminary, unaudited revenue of about $54.3 million for the nine months ended September 30, 2026, up 19% from $45.6 million a year earlier, and about $17.4 million for the third quarter. The company reaffirmed its expectation that full-year 2026 revenue will surpass $90 million, which matters to shareholders because it signals continued growth, though the figures are preliminary and the complete third-quarter results are not yet reported.
Nine-month 2026 revenue of about $54.3 million, up $8.7 million, or 19%, from $45.6 million in the same period of 2025
Third-quarter 2026 revenue of about $17.4 million, compared with a record $17.1 million in the third quarter of 2025
Full-year 2026 revenue outlook of over $90 million reaffirmed; the company expects the fourth quarter to be its strongest ever
Figures are preliminary and unaudited; complete third-quarter results will be reported in the Form 10-Q
Cosmos Health reported second-quarter 2026 revenue of $18.99 million, up 28.8% from a year earlier, and said it was the highest second-quarter revenue in its history. The net loss widened to $6.09 million from $2.83 million, which the company attributed mainly to $2.65 million of non-cash charges, chiefly fair value adjustments on its financing arrangements.
Q2 2026 revenue was $18.99 million, up 28.8% from $14.75 million; first-half revenue was $36.91 million, up 29.7%.
Q2 2026 net loss was $6.09 million, compared with $2.83 million in Q2 2025; first-half net loss was $8.89 million versus $3.65 million.
Q2 2026 gross profit was $1.51 million, up 29.9%; excluding $0.33 million of sales discount reversals, adjusted gross profit was $1.84 million, up 58.4%.
The Board authorized a share repurchase of up to $5.0 million on June 26, 2026; the company has repurchased 5,112,000 shares for about $1.11 million as of this date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cosmos Health Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →